**ERIC International Meeting** *New frontiers in CLL Research* 25-27 October 2018

Barcelona

GRIC

european research initiative on CLL

# European Research Initiative on CLL (ERIC)



## **ERIC Information**

- Non-profit organization according to German law Klinik I für Innere Medizin, Universitätsklinikum Köln Kerpener Straße 62, 50937, Köln
- <u>Established on 31<sup>st</sup> January 2006</u>
- Executive office:
  - Hematology Department, Hospital Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain
- **PIC** Number: 930535939
- WP7 European Leukemia Net
- **Scientific WG EHA**









## **ERIC Membership**

### > 1057 Members

#### Distributed amongst 68 countries / 518 different institutions


#### Number of ERIC members (per year)





## **ERIC Membership**







## **ERIC Meeting in Figures**

- TOTAL 365 ATTENDEES
  - Delegates 210
  - Students/Trainees 47
  - Pharma/Industry 53
  - ✤ Faculty 42

#### FROM 32 COUNTRIES

0	Argentina
0	Australia
0	Austria
0	Belgium
0	Canada
0	Colombia
0	Czech Republic
0	Denmark
0	Estonia
0	France
0	Germany
0	Greece
0	Hong Kong
0	Hungary
0	Israel

- ItalyLatvia
- o Lithuania
- Netherlands
- Norway
- Poland
- Portugal
- o Romania
- o Russia
- o Serbia
- Spain
- o Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- United States



## **ERIC Mission & Activities**

To to improve the outcome of patients with chronic lymphocytic leukemia (CLL) and related diseases through basic, translational and clinical research

through collaborative effort at a European level

- Research Projects
- Publications
- Harmonization/Recommendations
- Meetings/Educational events



## **ERIC Mission & Activities**

To to improve the outcome of patients with chronic lymphocytic leukemia (CLL) and related diseases through basic, translational and clinical research

through collaborative effort at a International level

- Research Projects
- Publications
- Harmonization/Recommendations
- Meetings/Educational events



## **ERIC Mission & Activities**

To to improve the outcome of patients with chronic lymphocytic leukemia (CLL) and related diseases through basic, translational and clinical research

through collaborative effort at a International level

- Research Projects
- Publications
- Harmonization/Recommendations
- Meetings/Educational events

## Harmonization



**ZAP70** 

- IGHV genes

Letestu et al, Cytometry part B (2006)

Rawstron et al, Leukemia (2007) Rawstron et al, Leukemia (2014) Rawstron et al, Leukemia (2017)

Ghia et al, Leukemia (2007) Langerak et al, Leukemia (2011) Rosenquist et al, Leukemia (2017)

**TP53 aberrations** 

Zenz et al, Leukemia (2010) Pospisilova et al, Leukemia (2012) Benner et al, Haematologica (2014) Te Raa et al, Br J Haematol (2014) Malcikova et al, Leukemia (2018)

Novel gene mutations

Baliakas et al, Leukemia (2015)



## **TP53 Network**

- ERIC promotes and supports, through education, the:
  - Importance of testing for TP53 aberrations all cases needing therapy, before first and later lines of treatment
  - Adoption of appropriate diagnostic techniques to ensure reliable and comparable results
    Certification of laboratories
  - The countries in green have at least 1 certified centre
  - Besides Europe, ERIC also has certified centres in Brazil and Australia



## **IGHV Network**

- ERIC promotes and supports, through education, the:
  - Importance of immunogenetic analysis across the medical community before using CIT
  - Adoption of appropriate diagnostic techniques to ensure reliable and comparable results
    Certification of laboratories
  - The countries in blue have at least 1 certified centre
  - Besides Europe, ERIC also has certified centres in Argentina, Australia, Taiwan and USA





## **Educational Workshops**

#### HANDS-ON WORKSHOP ON IGHV GENE ANALYSIS IN CLL

1<sup>st</sup> 14-15 JUNE 2007, UPPSALA (SWEDEN)

2<sup>nd</sup> 9-11 OCTOBER 2008, PARIS (FRANCE)

3<sup>rd</sup> 24-25 SEPTEMBER 2009, THESSALONIKI (GREECE)

4th 6-7 APRIL 2011, STRESA (ITALY)

5<sup>th</sup> 26-27 SEPTEMBER 2013, BRNO (CZECH REPUBLIC)

6<sup>th</sup> 22-23 SEPTEMBER 2016, UPPSALA (SWEDEN)

#### ERIC WORKSHOP ON IGHV ANALYSIS IN CLL

23 MAY 2017 (TEL-AVIV, ISRAEL) 04 JULY 2018 (TEL-AVIV, ISRAEL)

NIH-ERIC WORKSHOP ON IGHV GENE ANALYSIS IN CLL 28-29 MARCH 2019 (BETHESDA, MARYLAND, USA)

IMMUNOGENETICS IN CLL IN THE NGS ERA (ONE DAY WORKSHOP)

24 NOVEMBER 2017, ROTTERDAM, (THE NETHERLANDS)

#### ERIC WORKSHOP ON TP53 ANALYSIS IN CLL

1<sup>st</sup> 1-3 OCTOBER 2015, MASARYK UNIVERSITY CAMPUS, BRNO (CZECH REPUBLIC) 2<sup>nd</sup> 7-8 NOVEMBER 2017, HOTEL LA PALMA, STRESA (ITALY)

#### INTERNATIONAL WORKSHOP BIOMARKERS IN CLL: THE ART OF SYNTHESIS

16-17 MARCH 2018 (BELGRADE, SERBIA)

INTERNATIONAL WORKSHOP BIOMARKER-GUIDED MANAGEMENT OF CLL 13 APRIL 2018 (MOSCOW, RUSSIA)



## **Scientific Programme**

#### Thursday, 25 October

14.00 – 14.15 Opening remarks P. Ghia

Session 1 – Setting the tone Auditorium Chairs: K. Rai and D. Catovsky	AUDITORIUM
14.15 – 14.45 A life in CLL: musings and practical considerations E. Montserrat	
14.45 – 15.15 CLL diagnosis: everything settled? A. Rawstron	
15.15 – 15.45 Personalizing decision making in CLL: the challenge of accurate risk stratification <i>G. Gaidano</i>	
Session 2 – CLL Pathogenesis: interacting subsystems Auditorium Chairs: F. Caligaris Cappio and E. Campo	AUDITORIUM
16.15 – 16.45 Microenvironmental interactions and signaling pathways in CLL S. Deaglio	
16.45 – 17.15 CLL cell dynamics N. Chiorazzi	
1 <mark>7.15 – 17.45 <b>Genomic discoveries in CLL</b> R. Rosenquist</mark>	
17.45 – 18.15 Aberrant cell processes in CLL-beyond genomic aberrations <i>I. Martín Subero</i>	
18.30 – 20.00 WELCOME RECEPTION	PORT VELL
Friday, 26 October	
Session 3 – CLL treatment: state-of-the-art Auditorium Chairs: E. Kimby and M. Keating	AUDITORIUM
09.30 – 10.00 Pathway inhibitors for CLL therapy <i>J. Barrientos</i>	AODITORIONI
10.00 – 10.30 Combining treatment modalities: useful or superfluous? <i>W. Wierda</i>	
10.30 – 11.00 Sequential therapy and mechanisms of resistance S. Stilgenbauer	
Session 4 – Looking to the future in CLL treatment Auditorium Chairs: J. Seymour and R. Foa	AUDITORIUM
11.30 – 12.00 What does the future hold - projections from real world evidence R. Foa	
12.00 – 12.30 New monoclonal antibodies T. Kipps	
12.30 – 13.00 Aiming at MRD eradication: why and how P. Hillmen	
Session 5 – The future of cellular therapies Auditorium Chairs: C. Moreno and J. Brown	AUDITORIUM
14.00 – 14.30 Stem cell transplantation <i>P. Dreger</i>	
14.30 – 15.00 CART-cells C. Turtle	



## **Scientific Programme**

#### Session 6 – Hands on workshops on clinically relevant biomarkers

To be repeated 3 times – twice on Day 2 and once on Day 3. Each participant will have the chance to attend 3 different workshops.

15.00 – 16.30 Tailorin	g treatment: clinical considerations Auditorium	AUDITORIUM
Moderator: F. Cymbal	ista Speakers: F. Bosch and A. Tedeschi	
15.00 – 16.30 Cell-int	rinsic biomarkers - Recurrent gene mutations: Room A1 TP53 and beyond	ROOM A1
Moderator: A. Wiestn	er Speakers: J Malcikova and LA Sutton	
15.00 – 16.30 Cell-ext	rinsic biomarkers: Immunogenetics Room A2+A3	ROOM A2+A3
Moderator: C. Belessi	Speakers: F. Davi and A. Agathangelidis	
15.00 – 16.30 Cell-int	rinsic biomarkers – Cytogenetics Room A4	ROOM A4
Moderator: D. Oscier	Speakers: B. Espinet and C. Haferlach	
17.00 – 18.30 Tailorin	g treatment: clinical considerations Auditorium	AUDITORIUM
Moderator: F. Cymbal	ista Speakers: F. Bosch and A. Tedeschi	
17.00 – 18.30 Cell-int	rinsic biomarkers - Recurrent gene mutations: Room A1 TP53 and beyond	ROOM A1
Moderator: A. Wiestn	er Speakers: J Malcikova and LA Sutton	
17.00 – 18.30 Cell-ext	rinsic biomarkers: Immunogenetics Room A2+A3	ROOM A2+A3
Moderator: C. Belessi	Speakers: F. Davi and A. Agathangelidis	
17.00 – 18.30 Cell-int	rinsic biomarkers – Cytogenetics Room A4	ROOM A4
Moderator: D. Oscier	Speakers: B. Espinet and C. Haferlach	



## **Scientific Programme**

#### Saturday, 27 October

Session 6 – Hands on workshops on clinically relevant biomarkers

09.15 – 10.45 Tailoring trea	atment: clinical considerations Auditorium	AUDITORIUM
Moderator: F. Cymbalista	Speakers: F. Bosch and A. Tedeschi	
09.15 – 10.45 Cell-intrinsic	biomarkers - Recurrent gene mutations: Room A1 TP53 and beyond	ROOM A1
Moderator: A. Wiestner	Speakers: J Malcikova and LA Sutton	
09.15 – 10.45 Cell-extrinsic	biomarkers: Immunogenetics Room A2+A3	ROOM A2+A3
Moderator: C. Belessi	Speakers: F. Davi and A. Agathangelidis	
09.15 – 10.45 Cell-intrinsic	biomarkers – Cytogenetics Room A4	ROOM A4
Moderator: D. Oscier	Speakers: B. Espinet and C. Haferlach	

Session 7 – Biomarker-aided clinical decision making in CLL: conclusions from the workshops and future perspectives Auditorium AUDITORIUM Chairs: A. Kater and K. Stamatopoulos

11.15 – 11.25 Conclusions on Cytogenetics B. Espinet and C. Haferlach	
11.25 – 11.35 Conclusions on Recurrent gene mutations J. Malcikova and LA Sutton	
11.35 – 11.45 Conclusions on Immunogenetics F. Davi and A. Agathangelidis	
11.45 – 12.05 Tailoring treatment: clinical considerations F. Bosch and A. Tedeschi	
12.05 – 12.30 Prognostication in CLL: the art of synthesis D. Rossi	
Session 8 – ERIC mission: improving CLL patient care Auditorium Chairs: P. Ghia and E. Montserrat	AUDITORIUM


- 12.50 13.10 Real World Evidence in CLL: the ERIC CLL Database A. Hadzidimitriou
- 13.10 13.30 Research within ERIC: in the spirit of collaboration R. Rosenquist
- 13.30 13.50 Setting standards: ERIC harmonization activities S. Pospisilova
- 13.50 14.00 Closing remarks P. Ghia



## **Join ERIC**

## Please join ERIC if you are not a member already

- Receive regular updates on ERIC activities
- Participate in ERIC projects
- Network with other CLL experts
- Get involved it's free
- Join by going to our webpage,



www.ericll.org and clicking on the "Membership" page



# THANK YOU VERY MUCH FOR YOUR ATTENTION

## www.ericll.org